Perspective Therapeutics, Inc. - Form 8-K Filing

Perspective Therapeutics, Inc. reported its financial results for the year ended December 31, 2025, and provided business highlights on March 16, 2026. The company announced that its lead program, VMT-α-NET, for neuroendocrine tumors, continues to show a favorable tolerability profile with durable disease control and deepening responses. Updated interim data from the VMT-α-NET study, including safety and anti-tumor activity, were presented. The company expects to have all patients in Cohort 2 with at least 48 weeks of follow-up by mid-2026. Clinical updates for all three programs are anticipated throughout 2026. Financially, as of December 31, 2025, the company had approximately $145 million in cash, cash equivalents, and short-term investments. A subsequent equity offering in February 2026 raised approximately $164 million, which is expected to fund operations into late 2027. Research and development expenses increased significantly to $84.2 million in 2025, including a $10.0 million impairment loss for a preclinical asset. General and administrative expenses were $30.2 million. The net loss for 2025 was $103.1 million, or $1.40 per share.